Oxaliplatin-Based Chemotherapy in Advanced Neuroendocrine Tumors: Clinical Outcomes and Preliminary Correlation with Biological Factors

201691 citationsJournal Articlebronze Open Access

Authors

Francesca Spada · European Institute of Oncology

Lorenzo Antonuzzo · Azienda Ospedaliero-Universitaria Careggi

Riccardo Marconcini · Azienda Ospedaliera Universitaria Pisana

Davide Radice · Cancer Research And Biostatistics

Andrea Antonuzzo · Azienda Ospedaliera Universitaria Pisana

Sergio Ricci · Azienda Ospedaliera Universitaria Pisana

Francesco Di Costanzo

Abstract

This analysis suggests that oxaliplatin-based chemotherapy can be active with a manageable safety profile in advanced NETs irrespective of the primary sites and tumor grade. The 80% DCR and 8-month PFS could justify a prospective study in NETs with intermediate biological characteristics, especially with pancreatic primary tumors.

Topics & Keywords

Neuroendocrine Tumor Research Advances Lung Cancer Research Studies Neuroblastoma Research and Treatments

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Neuroendocrinology

Volume 103, Issue 6, pp. 806-814

DOI: 10.1159/000444087

Field-Weighted Citation Impact: 4.41